UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

PloS one, 2019-01, Vol.14 (1), p.e0210593-e0210593

2019

Volltextzugriff (PDF)

Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion

Cell, 1997-11, Vol.91 (4), p.521-530

1997

Volltextzugriff (PDF)

IL-17-Secreting γδ T Cells Are Completely Dependent upon CCR6 for Homing to Inflamed Skin

The Journal of immunology (1950), 2017-11, Vol.199 (9), p.3129-3136

2017

Volltextzugriff (PDF)

Seven structures of atypical chemokine receptor 3 reveal the molecular bases for its promiscuity and signaling bias

The FASEB journal, 2022-05, Vol.36 (S1), p.n/a

2022

Volltextzugriff (PDF)

A new class of membrane-bound chemokine with a CX3C motif

Nature (London), 1997-02, Vol.385 (6617), p.640-644

1997

Volltextzugriff (PDF)

Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.276-276

2017

Volltextzugriff (PDF)

392 PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-65-A-65

2009

Volltextzugriff (PDF)

Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES

Nature (London), 1990-10, Vol.347 (6294), p.669-671

1990

Volltextzugriff (PDF)

MO253A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY (LUMINA-1 STUDY) TO EVALUATE THE SAFETY AND EFFICACY OF CCX140 IN SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROISS (FSGS)

Nephrology, dialysis, transplantation, 2021-05, Vol.36 (Supplement_1)

2021

Volltextzugriff (PDF)

Kidney C5aR Is Expressed in Resident Macrophages, Tubular Epithelial Cells, and in Association With Fibrosis: SA-PO633

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.778-778

2022

Volltextzugriff (PDF)

Effect of Avacopan, a Selective C5a Receptor Inhibitor, on C3G Histologic Index of Disease Chronicity: PO2539

Journal of the American Society of Nephrology, 2021-10, Vol.32 (10S), p.B9-B10

2021

Volltextzugriff (PDF)

T1143 A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease

Gastroenterology (New York, N.Y. 1943), 2008, Vol.134 (4), p.A-493-A-493

2008

Volltextzugriff (PDF)

A human T cell-specific molecule is a member of a new gene family. 1988

The Journal of immunology (1950), 2009-04, Vol.182 (7), p.3947-3954

2009

Volltextzugriff (PDF)

Complement C5a Receptor Inhibitor Avacopan Improves Renal Function in ANCA Vasculitis: SU-OR32

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.53-53

2020

Volltextzugriff (PDF)

Complement C5a Receptor in Macrophage-Mediated Renal Inflammation and Fibrosis in Lupus Nephritis: PO2451

Journal of the American Society of Nephrology, 2021-10, Vol.32 (10S), p.749-749

2021

Volltextzugriff (PDF)

LB003A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY OF AVACOPAN IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS

Nephrology, dialysis, transplantation, 2020-06, Vol.35 (Supplement_3)

2020

Volltextzugriff (PDF)

FC 032THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WITH RENAL DISEASE

Nephrology, dialysis, transplantation, 2021-05, Vol.36 (Supplement_1)

2021

Volltextzugriff (PDF)

Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2593-2593

2022

Volltextzugriff (PDF)

Antagonists of chemokine receptor CCR9 synergize with anti-TNFα immunotherapy to reduce inflammation in the MDR1a−/− mouse model of colitis

The Journal of immunology (1950), 2020-05, Vol.204 (1_Supplement), p.233-233.3

2020

Volltextzugriff (PDF)

P0336INHIBITION C-C CHEMOKINE RECEPTOR TYPE 2 (CCR2) ON ACTIVATED KIDNEY PARIETAL EPITHELIAL CELLS REVEALS A NEW THERAPEUTIC APPROACH FOR CHRONIC KIDNEY DISEASES

Nephrology, dialysis, transplantation, 2020-06, Vol.35 (Supplement_3)

2020

Volltextzugriff (PDF)

Therapeutic Benefit of CCR2 Antagonism in a Model of Diabetic Nephropathy Suggests a Mechanism of Action Distinct from Nrf2 Activation: PO0943

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.324-325

2020

Volltextzugriff (PDF)

Abstract 1274: CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1274-1274

2021

Volltextzugriff (PDF)

P0973ALLOSTERIC C-C CHEMOKINE RECEPTOR TYPE 2 (CCR2) INHIBITION IMPROVES RENAL FUNCTION IN A MURINE MODEL OF DIABETIC NEPHROPATHY

Nephrology, dialysis, transplantation, 2020-06, Vol.35 (Supplement_3)

2020

Volltextzugriff (PDF)

IL36-Mediated Skin Inflammation Requires Signaling Through Chemokine Receptor CCR6

The Journal of immunology (1950), 2018-05, Vol.200 (1_Supplement), p.176-176.19

2018

Volltextzugriff (PDF)

Targeting Chemokine Receptors CCR6 and CXCR2 in A Murine Model Of IL-36a-Induced Pustular Psoriasis

The Journal of immunology (1950), 2019-05, Vol.202 (1_Supplement), p.133-133.7

2019

Volltextzugriff (PDF)

1 – 25 von 95

Suche als RSS-Feed

Aktive Filter

ThemaPsychology. Psychophysiology

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(84)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(14)
Animals
(7)
Biological And Medical Sciences
(5)
Fundamental And Applied Biological Sciences. Psychology
(5)
Social Sciences
(5)
Inhibition
(4)
Psychology
(4)
Visual Search
(4)
Calcium - Metabolism
(3)
Chemokine Ccl4
(3)
Chemotaxis, Leukocyte
(3)
Decision Making
(3)
Eye Movements
(3)
Female
(3)
Gastroenterology And Hepatology
(3)
Male
(3)
Molecular Sequence Data
(3)
Predictive Maintenance
(3)
Psychology, Multidisciplinary
(3)
Reaction Time
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion

IL-17-Secreting γδ T Cells Are Completely Dependent upon CCR6 for Homing to Inflamed Skin

Seven structures of atypical chemokine receptor 3 reveal the molecular bases for its promiscuity and signaling bias

A new class of membrane-bound chemokine with a CX3C motif

Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer

392 PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease

Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES

MO253A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY (LUMINA-1 STUDY) TO EVALUATE THE SAFETY AND EFFICACY OF CCX140 IN SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROISS (FSGS)

Kidney C5aR Is Expressed in Resident Macrophages, Tubular Epithelial Cells, and in Association With Fibrosis: SA-PO633

Effect of Avacopan, a Selective C5a Receptor Inhibitor, on C3G Histologic Index of Disease Chronicity: PO2539

T1143 A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease

A human T cell-specific molecule is a member of a new gene family. 1988

Complement C5a Receptor Inhibitor Avacopan Improves Renal Function in ANCA Vasculitis: SU-OR32

Complement C5a Receptor in Macrophage-Mediated Renal Inflammation and Fibrosis in Lupus Nephritis: PO2451

LB003A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY OF AVACOPAN IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS

FC 032THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WITH RENAL DISEASE

Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors

Antagonists of chemokine receptor CCR9 synergize with anti-TNFα immunotherapy to reduce inflammation in the MDR1a−/− mouse model of colitis

P0336INHIBITION C-C CHEMOKINE RECEPTOR TYPE 2 (CCR2) ON ACTIVATED KIDNEY PARIETAL EPITHELIAL CELLS REVEALS A NEW THERAPEUTIC APPROACH FOR CHRONIC KIDNEY DISEASES

Therapeutic Benefit of CCR2 Antagonism in a Model of Diabetic Nephropathy Suggests a Mechanism of Action Distinct from Nrf2 Activation: PO0943

Abstract 1274: CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

P0973ALLOSTERIC C-C CHEMOKINE RECEPTOR TYPE 2 (CCR2) INHIBITION IMPROVES RENAL FUNCTION IN A MURINE MODEL OF DIABETIC NEPHROPATHY

IL36-Mediated Skin Inflammation Requires Signaling Through Chemokine Receptor CCR6

Targeting Chemokine Receptors CCR6 and CXCR2 in A Murine Model Of IL-36a-Induced Pustular Psoriasis

Aktive Filter

Suchergebnisse filtern